Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:NGEN)

NervGen Engages Russo Partners LLC to Provide Public Relations Services

Newsfile 4 days ago

NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Newsfile 12 days ago

NervGen Completes $23 Million Bought Deal Financing

Newsfile March 28, 2024

Canadian Investment Regulatory Organization Trade Resumption - NGEN

Canada NewsWire March 21, 2024

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING

Canada NewsWire March 21, 2024

Canadian Investment Regulatory Organization Trading Halt - NGEN

Canada NewsWire March 21, 2024

NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company

Newsfile February 21, 2024

NervGen Pharma Grants Stock Options

Newsfile February 20, 2024

NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Newsfile February 15, 2024
View More News ››

Opinion & Analysis (TSXV:NGEN)

Can NervGen keep a lid on explosive news?

Knox Henderson March 20, 2024

Is this stunning 'evidence' that NervGen has the goods?

Knox Henderson February 1, 2024

NervGen Pharma: A “Blockbuster Drug” in the Making?

Stockhouse Editorial June 28, 2021

Alzheimer’s Breakthrough: Why the Experts are Betting on NervGen

Stockhouse Editorial April 7, 2021

Cracking the Code to Society’s Most Feared Disease

Stockhouse Editorial February 10, 2020
View More Opinion ››

Bullboard Posts (TSXV:NGEN)

PR Firm

This reeks of desperation. Makes zero sense. If results are positive then it will sell itself. Maybe they are gearing up for a stock...
ENEMENEMYNEMO - 4 days ago

Sedar filings HINT at inconclusive evidence (more testing)?

I conducted a review of the insider buying from February 15th 2024 to date.   The date of February 15th is when there were...
deepoil0808 - 4 days ago

UGLY chart speaks VOLUMES

I am thinking out loud.    If the treatment really worked we would have seen a soaring stock price as results are evident by...
deepoil0808 - April 9, 2024

Stock sharply down from $ 3.80/share (leaked results???)

Stock has dropped SHARPLY from $ 3.80 per share. Sadly, shareholders are always the last to know.   From reading the chart one...
deepoil0808 - March 26, 2024

RE:Bought deal RAISES questions. Why now?

the insider your referring to that sold was a director exercising stock options that were expiring. They only had enough cash for this...
holliganz - March 22, 2024

Bought deal RAISES questions. Why now?

Stock has plunged from +/- $ 3.80 to $ 2.48 today, a big drop. One insider sold +/- 30% of their holdings at $ 3 Market place published...
deepoil0808 - March 21, 2024
View more Bullboard ››

Silver Range Resources Ltd

Silver Range Resources Ltd

Silver Range Resources Ltd. is a Canada-based mineral exploration company. The Company’s mineral property interests include ...
View More »